Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSP NASDAQ:MRUS NYSE:RCUS NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$56.26+0.7%$56.73$30.04▼$71.13$5.08B1.811.76 million shs2.00 million shsMRUSMerus$69.58-0.3%$64.09$33.19▼$70.65$5.28B1.19529,666 shs1.24 million shsRCUSArcus Biosciences$11.50$10.02$6.50▼$18.98$1.22B0.83721,220 shs711,202 shsTGTXTG Therapeutics$32.16-0.9%$32.38$21.16▼$46.48$5.15B1.881.95 million shs2.39 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics+0.66%+2.55%-2.78%+36.03%+23.81%MRUSMerus-0.32%+3.13%+3.71%+27.41%+38.39%RCUSArcus Biosciences-0.04%-5.89%+14.31%+24.32%-32.27%TGTXTG Therapeutics-0.92%-0.16%+15.39%-10.69%+39.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$56.26+0.7%$56.73$30.04▼$71.13$5.08B1.811.76 million shs2.00 million shsMRUSMerus$69.58-0.3%$64.09$33.19▼$70.65$5.28B1.19529,666 shs1.24 million shsRCUSArcus Biosciences$11.50$10.02$6.50▼$18.98$1.22B0.83721,220 shs711,202 shsTGTXTG Therapeutics$32.16-0.9%$32.38$21.16▼$46.48$5.15B1.881.95 million shs2.39 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics+0.66%+2.55%-2.78%+36.03%+23.81%MRUSMerus-0.32%+3.13%+3.71%+27.41%+38.39%RCUSArcus Biosciences-0.04%-5.89%+14.31%+24.32%-32.27%TGTXTG Therapeutics-0.92%-0.16%+15.39%-10.69%+39.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.47Hold$71.6027.27% UpsideMRUSMerus 3.08Buy$88.7527.55% UpsideRCUSArcus Biosciences 2.75Moderate Buy$21.1483.85% UpsideTGTXTG Therapeutics 2.75Moderate Buy$46.2543.81% UpsideCurrent Analyst Ratings BreakdownLatest RCUS, TGTX, MRUS, and CRSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025CRSPCRISPR TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/25/2025MRUSMerusIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$90.008/25/2025MRUSMerusAlliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$90.008/7/2025CRSPCRISPR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$65.00 ➝ $80.008/7/2025RCUSArcus BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$26.00 ➝ $25.008/6/2025CRSPCRISPR TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$42.00 ➝ $56.008/6/2025MRUSMerusHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/6/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$97.00 ➝ $96.008/5/2025CRSPCRISPR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$82.008/5/2025CRSPCRISPR TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$38.00 ➝ $42.007/22/2025CRSPCRISPR TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$79.00 ➝ $78.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$37.31M137.14N/AN/A$22.64 per share2.48MRUSMerus$36.13M145.65N/AN/A$9.46 per share7.36RCUSArcus Biosciences$262M4.67N/AN/A$5.30 per share2.17TGTXTG Therapeutics$454.07M11.24$0.12 per share270.58$1.43 per share22.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$366.25M-$5.43N/AN/AN/A-1,229.43%-20.05%-17.09%11/4/2025 (Estimated)MRUSMerus-$215.33M-$5.50N/AN/AN/A-685.64%-50.28%-42.00%10/30/2025 (Estimated)RCUSArcus Biosciences-$283M-$3.17N/AN/AN/A-109.56%-55.96%-25.73%11/5/2025 (Estimated)TGTXTG Therapeutics$23.38M$0.3786.9232.16N/A13.31%26.05%9.58%11/3/2025 (Estimated)Latest RCUS, TGTX, MRUS, and CRSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025RCUSArcus Biosciences-$1.14-$1.1053+$0.0347N/A$32.86 million$160.00 million8/5/2025Q1 2025MRUSMerus-$1.17-$2.23-$1.06-$2.23$9.77 million$8.83 million8/4/2025Q2 2025CRSPCRISPR Therapeutics-$1.47-$1.29+$0.18-$2.40$6.44 million$0.89 million8/4/2025Q2 2025TGTXTG Therapeutics$0.32$0.17-$0.15$0.17$147.76 million$141.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR TherapeuticsN/A16.6116.61MRUSMerusN/A8.398.39RCUSArcus Biosciences0.184.504.50TGTXTG Therapeutics0.893.862.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%MRUSMerus96.14%RCUSArcus Biosciences92.89%TGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.30%MRUSMerus3.70%RCUSArcus Biosciences9.60%TGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics46090.95 million87.04 millionOptionableMRUSMerus3775.63 million72.84 millionOptionableRCUSArcus Biosciences500106.43 million96.21 millionOptionableTGTXTG Therapeutics290158.67 million141.78 millionOptionableRCUS, TGTX, MRUS, and CRSP HeadlinesRecent News About These CompaniesInsider Selling: TG Therapeutics (NASDAQ:TGTX) Director Sells 20,852 Shares of StockSeptember 13 at 6:38 AM | insidertrades.comWoodline Partners LP Takes $21.02 Million Position in TG Therapeutics, Inc. $TGTXSeptember 13 at 4:36 AM | marketbeat.comTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual MeetingSeptember 10 at 7:30 AM | globenewswire.comTG Therapeutics Begins Enrollment in Phase 3 Trial for Subcutaneous BRIUMVI in Patients with Relapsing Multiple SclerosisSeptember 8, 2025 | quiverquant.comQTG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced EnrollmentSeptember 8, 2025 | globenewswire.comCinctive Capital Management LP Purchases Shares of 14,145 TG Therapeutics, Inc. $TGTXSeptember 8, 2025 | marketbeat.comWhy TG Therapeutics (TGTX) Is Up 9.8% After Launching Another $100 Million Buyback ProgramSeptember 7, 2025 | finance.yahoo.comBanque Transatlantique SA Invests $610,000 in TG Therapeutics, Inc. $TGTXSeptember 6, 2025 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Shares Gap Up - Still a Buy?September 5, 2025 | marketbeat.comTG Therapeutics, Inc. (TGTX) Presents at Cantor Global Healthcare Conference 2025 TranscriptSeptember 4, 2025 | seekingalpha.com683 Capital Management LLC Reduces Holdings in TG Therapeutics, Inc. $TGTXSeptember 4, 2025 | marketbeat.comTG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 4, 2025 | globenewswire.comWhy Is TG Therapeutics (TGTX) Up 4.7% Since Last Earnings Report?September 3, 2025 | zacks.comTG Therapeutics completes share repurchase program, authorize new $100M programSeptember 3, 2025 | msn.comTG Therapeutics Board Authorizes New $100M Share Repurchase ProgramSeptember 3, 2025 | msn.comTG Therapeutics Completes $100 Million Share Repurchase Program and Authorizes New $100 Million Repurchase InitiativeSeptember 3, 2025 | quiverquant.comQTG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million ProgramSeptember 3, 2025 | globenewswire.comDriehaus Capital Management LLC Takes $30.55 Million Position in TG Therapeutics, Inc. $TGTXSeptember 1, 2025 | marketbeat.comRafferty Asset Management LLC Has $7.17 Million Holdings in TG Therapeutics, Inc. $TGTXAugust 30, 2025 | marketbeat.comJump Financial LLC Buys New Shares in TG Therapeutics, Inc. $TGTXAugust 30, 2025 | marketbeat.comTG Therapeutics to Participate in the Cantor Global Healthcare ConferenceAugust 28, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRCUS, TGTX, MRUS, and CRSP Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$56.26 +0.37 (+0.66%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$56.34 +0.08 (+0.13%) As of 09/12/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Merus NASDAQ:MRUS$69.58 -0.22 (-0.32%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$69.64 +0.06 (+0.09%) As of 09/12/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Arcus Biosciences NYSE:RCUS$11.50 0.00 (0.00%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$11.40 -0.10 (-0.83%) As of 09/12/2025 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.TG Therapeutics NASDAQ:TGTX$32.16 -0.30 (-0.92%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$32.11 -0.05 (-0.16%) As of 09/12/2025 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
